Systems, devices, and methods for administering cannabinoid mixtures
US-2024131279-A1 · Apr 25, 2024 · US
Nasal Administration
US2025090778A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025090778-A1 |
| Application number | US-202418643434-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 23, 2024 |
| Priority date | Apr 5, 2007 |
| Publication date | Mar 20, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
First claim
Opening claim text (preview).
1 - 92 . (canceled) 93 . A delivery device for delivering a powdered substance to the posterior region of a nasal cavity of a subject, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece, wherein the substance supply unit contains a powdered sumatriptan substance comprising a particle size distribution in which at least 10% of the particles are less than about 20 μm, at least 50% of the particles are less than about 50 μm, at least 50% of the particles are greater than about 30 μm, and at least 90% of the particles are less than about 150 μm, and wherein the powdered substance. 94 . The delivery device of claim 93 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate. 95 . The delivery device of claim 93 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants. 96 . The delivery device of claim 93 , wherein the substance supply unit contains a 10mg dose of the powdered sumatriptan substance. 97 . The delivery device of claim 93 , wherein the powdered sumatriptan substance has a particle size distribution in which at least 10% of the particles are less than about 10 μm and at least 90% of the particles are less than about 90 μm. 98 . A substance containing unit containing a powdered sumatriptan substance comprising a particle size distribution in which at least 10% of the particles are less than about 20 μm, at least 50% of the particles are less than about 50 μm, at least 50% of the particles are greater than about 30 μm, and at least 90% of the particles are less than about 150 μm, and wherein the powdered substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml. 99 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate. 100 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants. 101 . The substance containing unit of claim 98 , wherein the substance containing unit comprises a capsule. 102 . The substance containing unit of claim 98 , wherein the substance containing unit contains a 10 mg dose of the powdered sumatriptan substance. 103 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance has a particle size distribution in which at least 10% of the particles are less than about 10 μm and at least 90% of the particles are less than about 90 μm. comprises carboxymethylcellulose.
Assignees
Inventors
Classifications
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin · CPC title
Mouth · CPC title
Nose · CPC title
cooled · CPC title
Powder · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025090778A1 cover?
- A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powd…
- Who is the assignee on this patent?
- Optinose As
- What technology area does this patent fall under?
- Primary CPC classification A61M15/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Mar 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).